Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation
11.11.2026 15:58:00 CET | Business Wire | Press Release
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/
The Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, curated and convened by the Department of Health – Abu Dhabi (DoH) together with Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and Mubadala Bio.
Held from 20–22 October, the Summit attracted more than 17,300 visitors from 85 countries. It brought together health leaders, researchers, policymakers, investors and innovators to examine the practical steps needed to connect scientific advances with healthcare delivery and strengthen capabilities for identifying risks and intervening earlier.
The Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, curated and convened by the Department of Health – Abu Dhabi (DoH) together with Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and Mubadala Bio.
H.E. Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: “The Summit’s outcomes reflect Abu Dhabi’s ability to bring scientific, clinical and regulatory expertise together around shared health priorities, connecting that expertise through partnerships and programmes that sustain progress throughout the year. Our role is to enable researchers, healthcare providers and innovators to develop and evaluate solutions, building the evidence needed for their responsible application. Through the agreements, publications and programmes announced, we continue to expand opportunities for collaboration that support prevention and improve care in line with the needs of individuals and communities.”
Partnerships to advance drug discovery and clinical research
During the Summit, DoH signed an agreement with Isomorphic Labs to advance AI-enabled drug discovery, alongside an agreement with AstraZeneca and Cleveland Clinic Abu Dhabi to expand clinical research, with up to 30 clinical trials envisaged by 2030. These agreements support collaboration among researchers, life sciences companies and healthcare institutions, enabling research ideas to be developed and their potential applications explored and evaluated in clinical settings. DoH also launched its AI Clinician Framework to guide research and lay the foundations for the future regulation of autonomous AI clinical practice. It also launched a Trusted Research Environment, enabling research using health and genomic data within a secure environment.
These initiatives build on Abu Dhabi’s data infrastructure, clinical expertise and regulatory capabilities to support research and the responsible evaluation of emerging technologies.
Research in prevention and women’s health
DoH signed an agreement with WHOOP for a two-year preventive health research programme using wearable data. A joint study between DoH and ŌURA will also examine whether data from wearable devices can identify early warning signs of premature birth. Reproductive health partnerships included collaboration among DoH, Cleveland Clinic Abu Dhabi and Paterna to advance research; ART Fertility Clinics and Conceivable to explore AI applications in IVF; and collaboration with Merck to strengthen specialist education and professional development.
Publications to inform health policy and practice
Future Health released four whitepapers covering genomics and rare diseases, therapeutics, fertility, and embedding wearable technologies into the future of health and wellbeing, developed with EY, Strategy&, PwC Middle East and Deloitte respectively. The first three form part of the Abu Dhabi Blueprints series. Together, the four publications explore how scientific knowledge and technology can support prevention, earlier intervention and personalised care. The publications provide analysis and recommendations to inform policy and health system development, examining the scientific and practical requirements for the wider adoption of emerging technologies and knowledge.
New opportunities for innovators and entrepreneurs
Future Health opened Expressions of Interest for the second edition of the Future Health Impact Challenge. The Summit also premiered a documentary following the inaugural winners as they apply their solutions in communities around the world. The inaugural Challenge was delivered in collaboration with MIT Solve. Future Health also launched its Entrepreneurship Programme with Bridge for Billions. The programme will initially support around 50 health entrepreneurs across Africa and Asia, helping them develop businesses that respond to community needs and strengthen their sustainability and impact.
Selected participants will have the opportunity to connect with Abu Dhabi’s health innovation ecosystem at a later stage.
Year-round collaboration
The Summit featured 130 speakers across 45 sessions examining how AI, genomics, wearable technologies and investment can support prevention and improve care. Under the theme “To Sense Is to Predict”, discussions focused on the requirements for implementation, from scientific evidence and clinical evaluation to infrastructure and financing. The agreements and programmes announced create opportunities for continued work in research, clinical evaluation and entrepreneurship. Through its year-round activities, Future Health will continue to connect partners across longevity and precision medicine, digital health and AI, health system resilience and sustainability, and investment in life sciences.
Future Health invites researchers, innovators, investors and healthcare institutions to explore opportunities to participate in its programmes and collaborate through the initiatives announced during the Summit.
For more information, visit www.futurehealthinitiative.ae.
About Future Health – A Global Initiative by Abu Dhabi
Future Health is a year-round platform for global collaboration and transformative health innovation, held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council.
Bringing together health researchers, policymakers, business leaders, investors and entrepreneurs from across disciplines and geographies, Future Health drives collective action to strengthen health systems and unlock longer, healthier lives for all.
Through a year-round programme of research insights, publications, impact initiatives, Challenges, R&D funding, and cross-sector convenings, Future Health advances progress across four focus areas: longevity and precision medicine, health systems and sustainability, digital health and AI, and investment in life sciences.
Future Health is curated and convened by the Department of Health – Abu Dhabi and its Founding Partners: PureHealth, M42, Institute for Healthier Living Abu Dhabi, and Mubadala Bio. Mediclinic Middle East serves as Strategic Partner and Burjeel Holdings as Associate Partner.
For more information, visit www.futurehealthinitiative.ae and follow Future Health on: X, Instagram, LinkedIn and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261111545964/en/
Contacts
For media inquiries, please contact media@futurehealthinitiative.ae
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press Release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par
Starr Chile Assigned A Rating from AM Best11.11.2026 14:30:00 CET | Press Release
Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr
Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 14:22:00 CET | Press Release
Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an outcome. End customers for Epinal’s SEB include breathalyzer manufacturers, healthcare, mobile computers & clinical smartphones, handheld bio
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18 th and 19 th11.11.2026 12:30:00 CET | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Jefferies Global Healthcare Conference on November 18 and 19, 2026 and will participate in a fireside chat on November 18 at 9:00am GMT and a panel on November 19 at 10:30am GMT. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/avibSrFufLKeoLRAEgMxy6/eyqYNaU4UZTBAgMVip4JTx A live audio webcast of the panel will be accessible at the following link: https://event.summitcast.com/view/avibSrFufLKeoLRAEgMxy6/guest_book?session_id=H4EMMyKtX5Gd7TPGHGc3Si A replay of both webcasts will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) i
Lufthansa Selects Alcohol-Free Gewürztraminer Made with Solos Technology for Premium Allegris Business Class Experience11.11.2026 11:55:00 CET | Press Release
Lufthansa has selected BREAKAWAY Gewürztraminer, an alcohol-free wine from German winery Bergdolt-Reif & Nett, for its Allegris Business Class. Made using Solos technology, the wine was chosen following a blind tasting and is scheduled to be served from November 2026 to January 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111810839/en/ BREAKAWAY Gewürztraminer by Bergdolt-Reif & Nett, made with Solos technology. The selection marks a milestone for both partners, bringing their expertise to Lufthansa's premium passengers. Where winemaking meets innovation BREAKAWAY Gewürztraminer is made from a late-harvest wine, chosen for its distinctive aromatic character. Bergdolt-Reif & Nett, a fifth-generation family winery in Germany's Palatinate region, has developed alcohol-free wines since 2022. "That the wine impressed in a blind tasting is the most important point for me," says Christian Nett, winemaker and Managing Dir
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom